• Valion Bio agreed October 26, 2026, to privately place 4,717 Series C Non-Voting Convertible Preferred Shares for $4.72 million.
• The purchase price comprises $1.5 million in cash and $3.22 million retained by purchasers to satisfy overdue cash true-up payments.
• Series C purchasers also receive warrants to buy 2,524,343 common shares at an initial exercise price of $1.0092 per share.
• A separate private placement to 3i covers 50 Series B Non-Voting Convertible Preferred Shares for $50,000.
• The Series B placement includes warrants to purchase 1,539 common shares at an initial exercise price of $1.0092 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-033552), on October 27, 2026, and is solely responsible for the information contained therein.